All Stories

  1. Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer
  2. Re: Marcin Miszczyk, Pawel Rajawa, Takafumi Yanagisawa, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. In press.
  3. Comparing Performances of Predictive Models of Toxicity after Radiotherapy for Breast Cancer Using Different Machine Learning Approaches
  4. Machine-learning prediction of treatment response to stereotactic body radiation therapy in oligometastatic gynecological cancer: A multi-institutional study
  5. Impact of low skeletal muscle mass in oropharyngeal cancer patients treated with radical chemo-radiotherapy: A mono-institutional experience
  6. Real-world validation of Artificial Intelligence-based Computed Tomography auto-contouring for prostate cancer radiotherapy planning
  7. Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Ma...
  8. Radiation Therapy for Gestational Trophoblastic Neoplasia: Forward-Looking Lessons Learnt
  9. Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial
  10. Knowledge-based plan optimization for prostate SBRT delivered with CyberKnife according to RTOG0938 protocol
  11. Salvage Stereotactic Reirradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: A Retrospective Multicenter Study
  12. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study
  13. Granulosa cell tumors (GCTs) of the ovary: What is the role of radiotherapy?
  14. CT radiomic predictors of local relapse after SBRT for lung oligometastases from colorectal cancer: a single institute pilot study
  15. Ovarian Cancer Radiosensitivity: What Have We Understood So Far?
  16. In Regard to Zureick et al.
  17. Patient-specific forecasting of postradiotherapy prostate-specific antigen kinetics enables early prediction of biochemical relapse
  18. Accurate prediction of long-term risk of biochemical failure after salvage radiotherapy including the impact of pelvic node irradiation
  19. Knowledge-based automatic plan optimization for left-sided whole breast tomotherapy
  20. Toxicity of Hypofractionated Whole Breast Radiotherapy Without Boost and Timescale of Late Skin Responses in a Large Cohort of Early-Stage Breast Cancer Patients
  21. Could the association of sunitinib and stereotactic ablative radiotherapy lead to abscopal effect in metastatic renal cell carcinoma?
  22. Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study
  23. The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study
  24. Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups
  25. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study
  26. Gamma Knife radiosurgery as primary treatment of low-grade brainstem gliomas: A systematic review and metanalysis of current evidence and predictive factors
  27. Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis
  28. A Multicenter Large Retrospective Database on the Personalization of Stereotactic Ablative Radiotherapy for Lung Metastases From Colon-Rectal Cancer: The LaIT-SABR Study
  29. Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer
  30. 933 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD)
  31. Replacing Manual Planning of Whole Breast Irradiation With Knowledge-Based Automatic Optimization by Virtual Tangential-Fields Arc Therapy
  32. In Regard to Wages et al and Leite et al
  33. Toxicity of Hypofractionated Whole Breast Radiotherapy Without Boost in a Large “Real-Life” Cohort of Consecutive Early-Stage Breast Cancer Patients
  34. Impact of Gastrointestinal Side Effects on Patients’ Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study
  35. Clinical Implementation of Knowledge-Based Automatic Plan Optimization for Helical Tomotherapy
  36. Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a Gynaecology Study Group in the Italian Association of Radiation and Clinical Oncology (AIRO) review
  37. Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?
  38. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy
  39. Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study)
  40. Residual intra-fraction error in robotic spinal stereotactic body radiotherapy without immobilization devices
  41. Virtual Tangential-fields Arc Therapy (ViTAT) for whole breast irradiation: Technique optimization and validation
  42. How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study
  43. Which oligometastatic PCa should be treated on metastases only?
  44. Concomitant RT to primary and metastases in metastatic PCa
  45. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with “curative” intent
  46. Present clinical practice of breast cancer radiotherapy in Italy: a nationwide survey by the Italian Society of Radiotherapy and Clinical Oncology (AIRO) Breast Group
  47. Patients with MPM treated with high dose RT have higher survival
  48. Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR)
  49. A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups
  50. Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option
  51. European review of treatment strategies in prostate cancer PET positive relapse.
  52. EP-1993 Evidence of CTV underdosing due to anatomical changes during breast Helical Tomotherapy
  53. EP-1553 High-dose hypofractionated helical IG-IMRT in high-risk prostate cancer patients
  54. EP-1303 Hypofractionated adjuvant radiotherapy in elderly low risk breast cancer patients: loss or gain?
  55. EP-1640 Radical radiotherapy in elderly prostate cancer patients: a monoinstitutional experience
  56. PO-0973 Residual intra-fraction error in nonimmobilized patients treated with tracked robotic spinal SBRT
  57. EP-1482 Stereotactic rt in ovarian cancer: multicentric retrospective pooled analysis (MITO-RT project)
  58. Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series
  59. Important results from an Italian national survey on prostate cancer diagnosis and treatment.
  60. Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy
  61. Moderately Hypofractionated Helical IMRT, FDG–PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs
  62. Important results from an Italian national survey on prostate cancer diagnosis and treatment.
  63. FDG-PET/CT predictive value in MPM.
  64. Review of current status in prostate cancer PET positive relapse.
  65. EP-1593: Hypofractionated IGRT in high-intermediate and high/very-high risk prostate cancer patients
  66. EP-1221: Hypoxia imaging with 18F-FAZA PET/CT in Radiotherapy Planning for High Grade Gliomas
  67. EP-1191: Outcomes of a mono-institutional experience of IG-IMRT in Glioblastoma
  68. EP-1390: Salvage (postponed) hypofractionated tomotherapy for progressive MPM in patients with intact lungs
  69. Relationship between local relapse and distant metastases in prostate cancer
  70. 11C-Choline PET/CT based Helical Tomotherapy as Treatment Approach for Bone Metastases in Recurrent Prostate Cancer Patients
  71. Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR
  72. EP-1319: “Adjuvant”/ radical radiotherapy in prostate cancer patients with synchronous bone oligometastasis
  73. PO-0651: Five year outcome and soft tissue toxicity of breast cancer hypofractionated adjuvant radiotherapy
  74. EP-1159: Hypofractionated adjuvant radiotherapy and concomitant trastuzumab for breast cancer: 5-year results
  75. EP-1318: Is hypofractionation combined to WPRT effective in high risk prostate cancer patients?
  76. EP-1315: Prostate cancer lymph nodal disease: SBRT only or extensive prophylactic irradiation and boost?
  77. PO-0730: The independent benefit deriving from high doses and WPRT in salvage post-prostatectomy radiotherapy
  78. In Regard to Pommier et al
  79. Pros-IT CNR: an Italian prostate cancer monitoring project
  80. Why prostate cancer bone and lymph nodal metastases are different?
  81. Re: Daniel E. Spratt, Herbert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol. In press.
  82. In Regard to Perrier et al
  83. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I–II Study
  84. radiotherapy for prostate cancer lymph nodal recurrence
  85. EP-1079: Clinical outcomes in locally advanced oropharyngeal cancer 18FDG PET-guided dose escalation IMRT-SIB
  86. PO-0689: Outcome predictors for moderate hypofractionated tomotherapy in Malignant Pleural Mesothelioma
  87. PO-0753: Prospective evaluation of urinary function in patients with prostate cancer treated with RT
  88. EP-1349: Long term results of a phase I-II study of moderate hypofractionated IGRT in prostate cancer
  89. EP-1347: Could “radical” RT be a reasonable choice in bone oligometastatic prostate cancer patients?
  90. 553 Salvage tomotherapy choline PET/CT guided for prostate cancer lymph nodal recurrence
  91. 61 Prophylactic irradiation of pelvic lymph-nodal area after prostatectomy does not increase the risk of second neoplasms: A single institution analysis of 1109 patients with 10 years follow-up
  92. 684 Could “radical” RT be a reasonable therapeutic option in bone oligometastatic prostate cancer patients?
  93. 676 Prospective evaluation of urinary function in patients with prostate cancer treated with external beam radiation therapy
  94. Five-Year Outcomes and Late Toxicity in Prostate Cancer Patients Treated With Moderate Hypofractionated Helical Tomotherapy and Simultaneous Integrated Boost in a Phase 1-2 Study
  95. Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes?
  96. 623 Impact on anxiety and depression of urinary symptoms and incontinence after postprostatectomy radiotherapy in the first year after treatment
  97. PO-0719: Excellent 5 year outcome with image guided moderate hypofractionation in prostate cancer : phase I-II study results
  98. EP-1230: The level of lymphopenia inversely correlates with the risk for late urinary toxicity after WPRTfor prostate cancer
  99. OC-0321: Impact of urinary symptoms and incontinence on anxiety and depression 1 year after postprostatectomy radiotherapy
  100. EP-1157 FDG-PET guided dose escalation with TomoTherapy for locally advanced oropharyngeal cancer
  101. Higher-than-expected Severe (Grade 3–4) Late Urinary Toxicity After Postprostatectomy Hypofractionated Radiotherapy: A Single-institution Analysis of 1176 Patients
  102. Salvage therapy of small volume prostate cancer nodal failures: A review of the literature
  103. 11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients
  104. PO-0724: Outcome of Choline PET-CT guided salvage hypofractionated Tomotherapy for lymph-nodal recurrent prostate cancer
  105. High-Dose Moderately Hypofractionated Tomotherapy for Prostate Cancer: 5-Year Results
  106. PD-0316: Forward planned intensity modulated whole breast hypofractionated radiotherapy: results in 500 patients
  107. PO-0713: Salvage post-prostatectomy hypofractionated high dose Tomotherapy with prophylactic whole pelvic irradiation
  108. PO-0717: Five year results of high dose moderately hypofractionated tomotherapy for prostate cancer
  109. EP-1099: PET/CT guided tomotherapy in gynecologic cancers
  110. PO-0701: Toxicity and outcome of recurrent prostate cancer patients treated with 11-C Choline PET/CT-guided tomotherapy
  111. EP-1120: Stereotactic ablative radiotherapy for small lung tumors by means of TomoTherapy: preliminary results and toxicity
  113. PET-guided dose escalation tomotherapy in malignant pleural mesothelioma
  116. Megavoltage CT Images of Helical Tomotherapy Unit for Radiation Treatment Simulation: Impact on Feasibility of Treatment Planning in a Prostate Cancer Patient with Bilateral Femoral Prostheses
  117. Optimal Acute Toxicity for Concomitant Pelvic Irradiation with Tomotherapy in 153 Prostate Cancer Patients
  118. Hemithoracic Helical Tomotherapy (HT) for Malignant Pleural Mesothelioma (MPM): Early Results of a Dose Escalation Experience
  119. Dose Escalation for Prostate Cancer Using the Three-Dimensional Conformal Dynamic Arc Technique: Analysis of 542 Consecutive Patients
  120. Benefit on Biochemical Control of Adjuvant Radiation Therapy in Patients with Pathologically Involved Seminal Vesicles after Radical Prostatectomy
  121. Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer
  122. Cumulative meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or metastatic pancreatic cancer (PC)
  123. Androgen Ablation Therapy Does not Increase the Risk of Late Morbidity following 3D-conformal Radiotherapy of Organ-confined Prostate Cancer: The Experience of the European Institute of Oncology
  124. Finding dose–volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer
  125. Prognostic value of paranasopharyngeal extension of nasopharyngeal carcinoma (NPC)
  126. A GPC method to determine the composition of two component copolymers